Introduction {#s1}
============

Cardiac resynchronization therapy (CRT) has become an integral component of systolic heart failure (HF) therapy. Up to date there is a bulk of evidence for the beneficial effect of CRT in patients with moderate-to-severe clinical impairment, which includes improved quality of life, fewer hospitalizations and decreased mortality [@pone.0048926-Linde1]. The antiarrhythmic effects of CRT are well known [@pone.0048926-Barsheshet1]--[@pone.0048926-Arya1]. However there are also reports of proarrhythmic effects [@pone.0048926-Kurita1]--[@pone.0048926-Guerra1]. Intriguingly a meta-analysis of large clinical trials, involving patients being implanted with CRT-devices with defibrillator backup (CRT-D), could not show a reduction in device interventions due to ventricular arrhythmias (VA) [@pone.0048926-Bradley1]. Also despite careful patient selection and elaborate efforts in post-implantation management CRT is only successful in about 70% of patients [@pone.0048926-Singh1]. In patients responding to CRT left-ventricular reverse remodeling leads to a reduction of myocardial stretch and favorable neurohumoral changes [@pone.0048926-StJohnSutton1], [@pone.0048926-Ukkonen1]. Furthermore it can invoke profound changes on the (sub)cellular level [@pone.0048926-Sachse1], [@pone.0048926-Kass1]. Those effects might translate into a stabilizing effect on cardiac electrophysiology [@pone.0048926-Aiba1], [@pone.0048926-Chakir1]. Besides reduction in left-ventricular end-systolic volume (LVESV), as the established marker for mechanical remodeling, improved left ventricular systolic function (LVEF) could be a functional and easily obtainable alternative, which might be less afflicted by inter- and intra-observer variability [@pone.0048926-Knappe1]--[@pone.0048926-Penicka1]. Importantly, previous studies demonstrated that among CRT responders there is a decrease in VA [@pone.0048926-Ypenburg1]. However, whether an improvement of LVEF among CRT patients goes along with a decreased incidence of VA has not been prospectively evaluated.

To address the impact of an improved LV function on the occurrence of ventricular arrhythmias we analyzed the incidence of VA in CRT responders in comparison with non-responders.

Methods {#s2}
=======

1. Patients {#s2a}
-----------

126 consecutive heart failure patients who underwent implantation with a combined CRT and cardioverter-defibrillator device (CRT-D) were included. Eligibility for CRT was based on 1) moderate-to-severe HF (NYHA functional class III or IV) despite optimal conventional therapy, 2) LVEF ≤35% as demonstrated by echocardiographic assessment and 3) left bundle branch pattern on the electrocardiogram (ECG) with a QRS duration \>120 ms [@pone.0048926-Daubert1], [@pone.0048926-McMurray1].

This study was conducted with approval of the ethics review committees (ERC) appointed by each centre (Heinrich-Heine-University Duesseldorf: ERC of the medical faculty, Building 13.41, Moorenstrasse 5, 40225 Duesseldorf; RWTH Aachen: ERC of the medical faculty, Pauwelstrasse 30, 52074 Aachen). Data collection for scientific purposes was covered under a written consent given by the subjects upon admission to a teaching hospital.

2. CRT implantation {#s2b}
-------------------

CRT systems were implanted as previously described [@pone.0048926-Daubert1], [@pone.0048926-Len1], [@pone.0048926-Bax1]. The LV pacing lead was inserted by a transvenous approach through the coronary sinus into either the lateral or posterolateral cardiac vein whenever possible. All patients who received CRT devices had biventricular stimulation of the heart with right ventricular leads.

3. Follow -- up {#s2c}
---------------

### 3.1 Device evaluation {#s2c1}

All patients were seen for outpatient clinic visits at 4 weeks post CRT implantation and in 3-month intervals after implantation. A physician contacted patients who failed to present to the prescheduled routine visits by phone. All follow-up visits included an interview, physical examination, an ECG, and a device interrogation. From the device printouts incidence and type of arrhythmias were determined by two trained electrophysiologists. Analysis of the printouts was blinded. Shocks or antitachycardic pacing (ATP) were classified as appropriate when they occurred in response to VT or VF and as inappropriate when triggered by sinus or supraventricular tachycardia, T-wave oversensing, or electrode dysfunction [@pone.0048926-Gehi1], [@pone.0048926-Koneru1].

As described before the cycle length of the first ventricular arrhythmia triggering defibrillator (ICD) therapy and the average cut-off rate of the VT detection zone were standardized [@pone.0048926-Meyer1]. VT and VF zones were uniformly programmed with the same cut-offs for primary and secondary prevention patients. A VT-zone with primary application of ATP was programmed for CL from 450 ms to 300 ms, the VF-zone with immediate shock delivery was programmed for CL lower than 300 ms.

### 3.2 Clinical evaluation {#s2c2}

Heart failure symptoms were classified using the New York Heart Association (NYHA) score. Resting 2-dimensional echocardiography was performed at baseline and 6 months follow-up [@pone.0048926-McMurray1]. Biplane LVEF assessment according to Simpson\'s rule was obtained for each patient in the apical 2- and 4-chamber view [@pone.0048926-Lang1]. Volumetric parameters were acquired by biplane summation as reliably feasible in the individual [@pone.0048926-Daubert1]. Patients were classified as responders, based on an improvement in NYHA functional class by ≥1 and/or an improvement by ≥10% in LVEF 6 month after device implantation [@pone.0048926-Pouleur1], [@pone.0048926-Steffel1].

4. Statistical analysis {#s2d}
-----------------------

The primary end point was the occurrence of spontaneous sustained VT or VF leading to appropriate ICD intervention. Continuous data are expressed as mean ± standard deviation (SD). Categorical data are presented by frequencies and percentages. Differences in baseline characteristics and 6-month follow-up were evaluated using unpaired Student t-test and Fisher\'s exact test as appropriate. Data within patient groups (to compare the effect of CRT) were compared by the use of paired Student t-tests. Survival curves were calculated and graphically presented using the Kaplan-Meier method for censored failure time data. Cox regression analysis was performed to evaluate associations between risk factors at enrollment and appropriate VT/VF therapy. Variable selection process was performed in two steps. Starting with the univariate analysis of the potential association of baseline findings with the occurrence of sustained VT or VF. This step was used as a model building process with factors showing a p-value of less or equal to 0.2 being used in the corresponding multivariate statistical model. The resulting multivariate Cox regression models were stratified by responders, non-responders and ICM or DCM respectively. In this last step, factors were assessed as significant, if the p-value was less than 0.05. ROC analysis was conducted after prior testing by multivariate analysis. All analyses were performed using SAS® statistical software, V9.1.3 (SAS Institute, Cary, NC, USA).

Results {#s3}
=======

1. Patients {#s3a}
-----------

The baseline characteristics of patients are shown in [Table 1](#pone-0048926-t001){ref-type="table"}. There were no differences in clinical baseline characteristics between patients found to be responders or non-responders except for a slightly higher number of patients with secondary preventive implantation in the responder group. The cause of heart failure was ischemic in 65 patients (52%) and non-ischemic in 61 patients (48%).

10.1371/journal.pone.0048926.t001

###### Comparison of baseline clinical characteristics between responders and non responders.

![](pone.0048926.t001){#pone-0048926-t001-1}

                                   Responders (n = 74)   Non- Responders (n = 52)   p-value
  ------------------------------- --------------------- -------------------------- ---------
  Men, n (%)                             49 (66)                 36 (69)             0.847
  Age, years                              64±10                   64±12              0.537
  Body mass index, kg/m2                  28±4                     26±4              0.462
  QRS duration, ms                       160±19                   158±24              0.4
  NYHA class IV, n (%)                   13 (18)                  5 (10)             0.209
  LVEF, %                                 25±7                     24±8              0.742
  ICM, n (%)                             34 (46)                 31 (60)             0.15
  Cardiovascular history, n (%)                                                    
  Previous CABG                          10 (14)                 13 (25)             0.108
  Previous PCI                           16 (21)                 15 (29)             0.404
  NSVT                                   10 (14)                  7 (14)              1.0
  Aborted SCD                            20 (27)                  8 (15)             0.134
  Rhythm, n (%)                                                                    
  Sinus rhythm                           63 (85)                 43 (83)             0.806
  Atrial fibrillation                    11 (15)                  9 (17)             0.806
  Comorbidity, n (%)                                                               
  Diabetes                               30 (41)                 14 (27)             0.132
  Dyslipoproteinaemia                    51 (69)                 35 (67)             0.849
  Hyperuricaemia                         39 (53)                 24 (46)             0.587
  Hypertension                           51 (69)                 35 (67)             0.849
  Medication, n (%)                                                                
  Beta-blockers                          67 (91)                 48 (92)              1.0
  ACE-inhibitors/ARB                     73 (99)                 49 (94)             0.305
  Loop diuretics                         62 (84)                 48 (92)             0.184
  Spironolactone                         59 (80)                 39 (75)             0.664
  Digitalis                              40 (54)                 28 (54)              1.0
  Amiodarone                             17 (23)                 17 (33)             0.308
  Statins                                39 (53)                 31 (60)             0.471

ICM = ischemic cardiomyopathy; CABG = coronary artery bypass graft; CRT = cardiac resynchronization therapy; ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; NSVT = non-sustained ventricular tachycardia; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; SCD = sudden cardiac. death; All differences between responders and non-responders are statistically not significant.

2. CRT response {#s3b}
---------------

Mean LVEF increased within 6 month after CRT device implantation from 25±7% to 31±8% (p\<0.001), with a reduction in LVESV from 174±73 ml to 138±69 ml (p\<0.001). There were 74 (59%) patients, among our collective of 126 individuals, fulfilling the criteria for positive CRT response as established above ([Table 1](#pone-0048926-t001){ref-type="table"}). In the responder group the mean LVEF improved from 25±7% to 36±6% (p\<0.001), while in the non-responder group no significant increase occurred ([Figure 1](#pone-0048926-g001){ref-type="fig"}). Furthermore, in the responder group a decrease in LVESV from 176±72 ml to 122±68 ml (p\<0.001) was noted, while in the non-responder group no significant decrease in LVESV (baseline: 169±73, follow-up: 162±69; p = 0.521) occurred. This also applied for the development of NYHA classes. The baseline NYHA classes were matched between responders and non-responders. At the 6-month interval there was a statistically significant association of CRT-response with development of the NYHA class. In the responder group there was a significant shift of patients from NYHA class IV and III to lower classes ([Table 2](#pone-0048926-t002){ref-type="table"}).

![Development of mean left ventricular ejection fraction (EF) in the collectives with and without response to cardiac resynchronization therapy at baseline and at 6 months after device implantation.\
Error bars indicate standard deviation. While there is no increase in EF in the non-responder group, there is significant improvement in the responder group (\* = p\<0.0001; see also [Table 2](#pone-0048926-t002){ref-type="table"}).](pone.0048926.g001){#pone-0048926-g001}

10.1371/journal.pone.0048926.t002

###### Comparison of changes in NYHA functional class and left ventricular ejection fraction (LVEF) between responders and non-responders.

![](pone.0048926.t002){#pone-0048926-t002-2}

                               All Patients (n = 126)                    Responders (n = 74)             Non-Responders (n = 52)   p value (responders = vs. non-responders)  
  ------------------- ---------------------------------------- ---------------------------------------- ------------------------- ------------------------------------------- -------------------------------
  LVEF                                                                                                                                                                        
  Baseline                             25±7%                                    25±7%                             24±8%                              0.458                    
  6 months post CRT    31±8%[\*](#nt103){ref-type="table-fn"}   36±6%[\*](#nt103){ref-type="table-fn"}            24±7%                             \<0.001                   
  NYHA class                           n (%)                                    n (%)                             n (%)                                                       
  Baseline                             NYHA I                                   0 (0)                             0 (0)                              0 (0)                     fisher\'s exact testp = 0.152
                                      NYHA II                                   9 (7)                             3 (4)                             6 (12)                    
                                      NYHA III                                 99 (79)                           58 (78)                            41 (79)                   
                                      NYHA IV                                  18 (14)                           13 (18)                            5 (10)                    
  6 months post CRT                    NYHA I                                  13 (10)                           13 (18)                             0 (0)                     fisher\'s exact testp\<0.0001
                                      NYHA II                                  50 (40)                           47 (64)                             3 (6)                    
                                      NYHA III                                 46 (37)                           12 (16)                            34 (65)                   
                                      NYHA IV                                  17 (14)                            2 (3)                             15 (29)                   

There was as a significant shift of patients from NYHA class IV and III to lower classes in patients responding to CRT. Abbreviations: LVEF = left ventricular ejection fraction; CRT = cardiac resynchronization therapy; NYHA class = New York Heart Association functional heart failure classification;

 = p\<0.0001 for comparison against baseline.

3. Follow-up of responders vs. non-responders {#s3c}
---------------------------------------------

The mean duration of follow-up was 28±14 months (range 9 to 48 month). There were 10 (8%) deaths in our whole collective. Of those 3 occurred in the responder group and were all due to non-cardiac causes, the remaining 7 deaths occurred in the non-responder group and were all attributed to worsening heart failure. There were 8 hospitalizations due to worsening heart failure among 7 Patients in the responder group (11%) and 43 such hospitalizations among 22 patients in the non-responder group (42%). There were no heart transplantations in the responder group whereas there were 2 transplantations among the non-responders.

4. Incidence and therapy of ventricular arrhythmias {#s3d}
---------------------------------------------------

Patients in the responder group received less appropriate ICD therapy than patients in the non-responder group (35% vs. 58%, log-rank X^2^ = 7.5, p\<0.0061, [Figure 2A](#pone-0048926-g002){ref-type="fig"}). At the end of follow-up, the time between implant and first appropriate ICD therapy was comparable in both groups (19±13 months vs. 15±14 months, p = 0.09). Furthermore, the cycle length of the first ventricular arrhythmia triggering ICD therapy was the same in both groups (responders: 301±48 ms; non-responders: 290±54 ms, p = 0.43). The likelihood of arrhythmia events decreased with increasing LVEF during follow-up (40% vs. 58%, log-rank X^2^ = 5.7, p\<0.0168). By employing ROC analysis an EF increase by \>7% during CRT was determined as a significant cut-off value ([Figure 3](#pone-0048926-g003){ref-type="fig"}) to distinguish individuals with a lower risk of VA occurrence ([Figure 2B](#pone-0048926-g002){ref-type="fig"}). The group of patients with secondary preventive ICD-implantation had greater quota of individuals receiving appropriate ICD therapies (n = 20, 71%) than the group of patients with primary preventive indication (n = 36, 37%, p = 0.0002). There was no significant difference in the incidence of appropriate ICD therapies between in patients with ischemic or non-ischemic heart failure.

![Kaplan-Meier curves of survival free from appropriate implantable cardioverter-defibrillator (ICD) therapy for (A) responders (composite end-point of LVEF increase \>10% and/or reduction of 1 NYHA class) and non-responders to resynchronization therapy and (B) in patients with improvement of left ventricular ejection fraction (LVEF) by more respectively 7 or less percent at 6 month after device implantation (as determined by ROC as analysis).\
In themselves the survival curves illustrate the significant impact of response to CRT (p = 0.0061) as well as the development of LVEF under CRT (p = 0.0168) on the occurrence of ventricular arrhythmia.](pone.0048926.g002){#pone-0048926-g002}

![ROC analysis demonstrating the sensitivity and specificity for an increase in EF by \>7% as a predictor of ICD therapy (area under the curve = 0.606; standard error = 0.0503; 95% confidence interval = 0.515--0.692; p = 0.0352).](pone.0048926.g003){#pone-0048926-g003}

We also conducted a subgroup analysis comparing non-responders with first VA event in the initial 6 months of CRT (early events) against with first event beyond this period (late events). In this analysis patients with early events had a lesser increase in LVEF during the first 6 months (11.7±27.9% vs. 5.9±24.1%), although the number of patients in those groups was small (n = 28 vs. 24) and the effect was statistically not significant (p = 0.435).

5. Predictors of ICD therapy {#s3e}
----------------------------

Cox Regression analysis of clinical baseline parameters indicates that patients on therapy with an ACE inhibitor or an angiotensin receptor antagonist, as well as females a significantly have a reduced risk of VA (HR = 0.24--0.47, p\<0.05). Also response to CRT therapy by 6 months after implantation is associated with an reduced risk for VA (HR = 0.53, p\<0.05). Secondary preventive indication for device implantation is associated with a significantly higher risk of such events (HR = 3.13, p\<0.05) ([Table 3](#pone-0048926-t003){ref-type="table"}).

10.1371/journal.pone.0048926.t003

###### Cox Regression analysis of the correlation of selected patient characteristics with the incidence of ventricular arrhythmias (VA) during cardiac resynchronization therapy (CRT).

![](pone.0048926.t003){#pone-0048926-t003-3}

                              b         SE        P      Exp(b)   95% CI of Exp(b)
  ----------------------- ---------- -------- --------- -------- -------------------
  age \>65 years            0.1216    0.2968   0.6819    1.1294   0.6331 to 2.0148
  female sex               −0.7467    0.3538   0.03483   0.4739   0.2377 to 0.9448
  CAD                      −0.04497   0.3125   0.8856    0.9560   0.5198 to 1.7584
  secondary preventive      1.1420    0.3203   0.00036   3.1329   1.6777 to 5.8503
  ACEI/ATR antagonist      −1.5886    0.6600   0.01609   0.2402   0.05664 to 0.7397
  betablocker              −0.4194    0.5329   0.4312    0.6574   0.2326 to 1.8584
  digitalis                 0.2583    0.3081   0.4019    1.2947   0.7100 to 2.3610
  spironolactone           0.16669    0.4093   0.6835    1.1816   0.5319 to 2.6248
  responder at 6 months    −0.6370    0.2959   0.03133   0.5289   0.2970 to 0.9417

Patients on therapy with an ACE inhibitor or an angiotensin receptor antagonist, as well as females and responders to CRT show a significantly risk of VA (HR = 0.24--0.53, p\<0.05). Secondary preventive indication for device implantation is associated with a significantly higher risk of such events (HR = 3.13, p\<0.05). Abbreviations: b = beta, SE = standard error, P = p-value, Exp(b) = hazard ratio (HR), CI = confidence interval.

6. Inappropriate ICD therapy {#s3f}
----------------------------

Twelve patients (9.5%) experienced inappropriate ICD shocks. The trigger for inappropriate therapy was atrial arrhythmia in 3 patients, sinus tachycardia in 1 patient, T-wave oversensing in 7 patients, and sensing of diaphragm potentials in 1 patient. Of these 12 patients 7 belonged to the responder group and 5 to the non-responder group, representing 9.5 respectively 9.6% of each group (p = 1.0).

Discussion {#s4}
==========

The key findings of this study are: (1.) the incidence of VA is reduced in patients responding to CRT during long-term follow-up. (2.) An increase of LVEF during the first 6 months after commencement of therapy goes along with a decreased incidence VA.

Although there is some evidence favoring antiarrhythmic effects of CRT [@pone.0048926-Arya1], [@pone.0048926-Kis1], [@pone.0048926-Aiba2], it\'s impact on arrhythmia susceptibility is not fully understood with multiple studies providing differing outcomes. Some studies reported a decrease of the number of VA after CRT [@pone.0048926-Higgins1]--[@pone.0048926-Lellouche1]; however others reported the opposite [@pone.0048926-Guerra1], [@pone.0048926-DiCori1]. One meta-analysis of large randomized CRT trials found no significant effect of CRT on sustained VA occurrence compared with ICD therapy only [@pone.0048926-Bradley1]. Additionally, a recent meta-analysis including data from the extension phase of Cardiac Resynchronization-Heart Failure (CARE-HF) provided evidence against a benefit of CRT alone on risk of sudden cardiac death (SCD) [@pone.0048926-Cleland1].

In a recent study Lin et al. [@pone.0048926-Lin1] could not determine any benefit of CRT on the occurrence of VA in a collective of patients undergoing an upgrade from ICD to CRT-D. This might be due to the relatively small sample size and more importantly to the preselection of the patients. All patients included in this study were previously implanted with an ICD, demonstrating a markedly higher risk for VA. Our patient collective in contrast included patients on an "all comers" basis and thus was more heterogenous.

The time course of VA incidence in our study appears to be in line with reports from other investigators, delineating a period from 3 to 12 months after implantation in which electrical reverse remodeling seems to occur [@pone.0048926-Kronborg1], [@pone.0048926-Boriani1]. This seems to apply to responders as well as to non-responders, implying that even in non-responders there seems to be some consequence of CRT - just not to the extent as in responders.

We emphasize that the population of our uncontrolled non-randomized observational study is smaller than that included in recent hallmark trials looking for benefit from CRT responding. However, our study design pursued a different aim and was conducted to investigate the incidence of VA in association to improved cardiac function in daily clinical practice.

Contradictory to evidence from previous studies [@pone.0048926-Boriani2], in the presented COX regression analysis of baseline patient characteristics treatment with beta-blockers had no significant effect on VA incidence (HR = 0.657, p = 0.431), This might be in part due to the overpowering impact of other factors in this statistical model. In addition, relatively low beta-blocker dosing, due to adverse effects [@pone.0048926-Kis1], might be of importance but remains speculative.

Also we chose a definition of reverse remodeling that diverged in some points from the definition used in other current studies. This might impede the comparability of our results.

For the assessment of functional myocardial remodeling under CRT we monitored the development of LVEF during patient follow-up visits. Although LVESV has been shown to be a good indicator of reverse remodeling in previous publications, LVEF was chosen as it is well established and can be measured with comparably low intra- and inter-observer variation during routine echocardiography [@pone.0048926-Jenkins1]. Nevertheless this might limit comparability of the presented data.

Defining a positive response to CRT is still crucial. Defining a response as \>10% increase of LVEF and/or an improvement of NYHA functional class by ≥1 may limit the number of patients fulfilling these criteria. Also there exist more elaborate classifications of HF, which might aid in the better discrimination of HF stages (e.g. Metra et al. [@pone.0048926-Metra1]).

However this cut-off is well established in the literature and the observed responder rate of about 70% in our patient population with an LVEF improvement by 7% is in line with various reports [@pone.0048926-Linde2], [@pone.0048926-Higgins2]. In another recent publication Ypenburg et al. nicely demonstrated that a response to CRT, defined as an improvement in NYHA functional class, was associated with a lower risk of receiving ICD therapy [@pone.0048926-Cleland1], [@pone.0048926-Ypenburg2].

Herein, we provide evidence during a longer follow-up that improved systolic LV function is associated with a reduced incidence of VA.

Importantly, a possible explanation for the relatively high number of patients with adequate ICD interventions might be early detection and first-line treatment of VA with ATP that may be in fact nsVT. Therefore, ICD therapy would not be a reliable surrogate for SCD, because some VA would likely have terminated spontaneously in the absence of the ICD [@pone.0048926-Guerra1]. However, to determine the risk of sudden cardiac death was beyond the scope of the present study.

5. Conclusion {#s4a}
-------------

The present findings suggest that improvement of LVEF under CRT in patients with moderate-to-severe heart failure and left bundle branch block, apart from hemodynamic benefits, goes along with a decreased incidence of ventricular arrhythmias.
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